Purpose: To prospectively evaluate the short-term toxicoses associated with pegylated-liposomal doxorubicin (Doxil) administered to dogs with measurable tumors of various histologic types and sites. Preliminary information regarding efficacy was also generated.
Methods: A group of 51 dogs with histologically confirmed malignancies received a total of 103 Doxil treatments given i.v. every 3 weeks at dosages ranging from 0.75 to 1.1 mg/kg in the context of a phase I dose-escalation trial. Acute and short-term toxicities as well as tumor response and duration of response were characterized.
Results: The maximally tolerated dose in tumor-bearing dogs was established as 1.0 mg/kg i.v. every 3 weeks. The dose-limiting toxicity was a cutaneous toxicity clinically resembling palmar-plantar erythrodysesthesia (PPES). An overall response rate of 25.5% was observed with five complete responders and eight partial responders.
Conclusions: Doxil appeared to be well tolerated at dosages similar to those tolerated for free doxorubicin in tumor-bearing dogs. PPES was the dose-limiting toxicity encountered, rather than myelosuppresion as is the case with free doxorubicin in dogs. Doxil as a single agent may have a broad spectrum of activity and deserves further evaluation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s002800050591 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells.
J Clin Invest
November 2024
Department of Digestive Diseases and National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Liposomal drug delivery systems have revolutionized traditional cytotoxic drugs. However, the relative instability and toxicity of the existing liposomal drug delivery systems compromised their efficacy. Herein, we present Rg3-lipo, an innovative drug delivery system using a glycosyl moiety-enriched ginsenoside (Rg3).
View Article and Find Full Text PDFToxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model.
Toxins (Basel)
August 2024
Animal Cancer Care and Research Program, University of Minnesota, St. Paul, MN 55108, USA.
EGFR-targeted therapies are efficacious, but toxicity is common and can be severe. Urokinase type plasminogen activator receptor (uPAR)-targeted drugs are only emerging, so neither their efficacy nor toxicity is fully established. Recombinant eBAT was created by combining cytokines EGF and uPA on the same single-chain molecule with truncated toxin.
View Article and Find Full Text PDFGenomic profiling of cell-free DNA from dogs with benign and malignant tumors.
BMC Res Notes
September 2024
Research & Development, TwixBio, Shenzhen, China.
Article Synopsis
- Cancer is the leading cause of death in adult dogs, with a significant chance (one-third) of developing it during their lifetime.
- A study using shallow whole-genome sequencing analyzed blood cell-free DNA from four dogs with tumors (one benign and three malignant) and 38 healthy dogs.
- Results showed that healthy dogs and the benign tumor dog had no copy number aberrations, while the malignant tumor dogs exhibited noticeable copy number variations and shorter DNA fragment sizes, indicating the potential for non-invasive cancer detection in dogs.
Cytotoxic T cells drive doxorubicin-induced cardiac fibrosis and systolic dysfunction.
Nat Cardiovasc Res
August 2024
Department of Immunology, Tufts University, Boston, MA, USA.
Doxorubicin, the most prescribed chemotherapeutic drug, causes dose-dependent cardiotoxicity and heart failure. However, our understanding of the immune response elicited by doxorubicin is limited. Here we show that an aberrant CD8 T cell immune response following doxorubicin-induced cardiac injury drives adverse remodeling and cardiomyopathy.
View Article and Find Full Text PDFFeasibility assessment of inspiration breath-hold motion management for tumor tracking during cone-beam computed tomography for setup and radiotherapy in Veterinary Medicine: A pilot study.
Vet Radiol Ultrasound
November 2024
Lloyd Veterinary Medical Center, Iowa State University College of Veterinary Medicine, Ames, Iowa, USA.
Radiotherapy (RT) for lung or liver tumors can be challenging due to respiration-induced organ motion (RIOM). There are some methodological solutions to minimize RIOM. We explored a new approach to evaluate the feasibility and reproducibility of RIOM during RT with five total client-owned tumor-bearing animals using a remote-triggered breath-hold ventilator under general anesthesia during image acquisition and RT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!